Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8485288 | 0.83 | GAA (0.51) | GAACYP4F2CYP4A11SMN1; SMN2MEN1 | |
| SCHEMBL3542659 | 0.83 | GAA (0.48) | GAASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL31650310 | 0.82 | P2RX7 (0.46) | GAASMN1; SMN2KMT2AALDH1A1TSHR | |
| SCHEMBL3545681 | 0.82 | GAA (0.47) | GAASMN1; SMN2MEN1KMT2ASLC6A2 | |
| SCHEMBL8484148 | 0.82 | GAA (0.50) | GAASMN1; SMN2MEN1KMT2ASLC6A2 | |
| SCHEMBL8485004 | 0.80 | GAA (0.53) | GAACYP4F2CYP4A11SMN1; SMN2MEN1 | |
| SCHEMBL1807144 | 0.80 | HSD11B1 (0.54) | GAAMEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL3538194 | 0.79 | EPHX2 (0.41) | SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL434932 | 0.74 | GAA (0.48) | GAACYP4F2CYP4A11SMN1; SMN2MEN1 | |
| SCHEMBL1805474 | 0.74 | KAT2B (0.36) | GAASMN1; SMN2MEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | GAA 171/4885CYP4F2 487/4885CYP4A11 800/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | GAA 163/4885CYP4F2 549/4885CYP4A11 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.